×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Prostate Cancer

Feature Video
Receiving a diagnosis of prostate cancer can be frightening and confusing. Understanding the details of your specific cancer and how they relate to your prognosis and treatment planning is an important first step toward shared decision-making between you and your physicians. In these CURE Connections programs you will learn the meaning of the PSA test, prostate cancer staging and grading, and how these factors are used to determine which treatment approach is right for you. Management of prostate cancer related symptoms, available treatments, and how to deal with side effects are also discussed. In addition, you will hear from patients and caregivers about their personal experiences with prostate cancer.
Kristie L. Kahl
What do Bill Nye the Science Guy, fashion designer Michael Kors and one very special prostate cancer advocate all have in common? Blue jackets, a runway and the ultimate goal of raising awareness for prostate cancer.
Jason Harris
The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.
Kristie L. Kahl
With just one catwalk, the Prostate Cancer Foundation brought together celebrities, fashion designers and a special patient advocate to raise awareness for prostate cancer.
Jason M. Broderick
The Food and Drug Administration (FDA) approved Erleada (apalutamide) for the treatment of patients who have nonmetastatic castration-resistant prostate cancer (CRPC). The drug is now the first FDA-approved treatment in this setting.
 
Kristie L. Kahl
More than 12 percent of men with prostate cancer tested positive for hereditary mutations of cancer-causing genes, according to study results presented at the 2018 Genitourinary Cancers Symposium.
 
Silas Inman
Janssen Biotech announced that the Food and Drug Administration has approved Zytiga (abiraterone acetate) in combination with prednisone for high-risk castration-sensitive prostate cancer.
Kristie L. Kahl
A study of 1,334 men diagnosed with non-metastatic prostate cancer showed a significantly increased risk of recurrence in those who consumed more than four servings of whole milk per week. 
Kristie L. Kahl
The Virtual Environment Radiotherapy Training (VERT™) system, originally designed to teach medical students and physicians about administering radiation therapy, is being used to explain to people who have prostate cancer what their treatment will look like. 
Jason M. Broderick
The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.
Kristie L. Kahl
Data from a pilot study showed an added benefit from the incorporation of extra virgin olive oil into the diets of men with low-risk prostate cancer. As a result, this dietary modification could lead to weight loss, while also helping the body to absorb compounds with anticancer properties.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other